Overview
- In a Nov. 9 Sunday Times interview, Ramsay ruled out creating smaller or specialized menus for patrons taking GLP‑1 drugs such as Ozempic and Mounjaro.
- He delivered an obscenity‑laced dismissal of the concept and argued that restaurateurs should not compensate for overeating.
- The comments followed The Fat Duck’s September launch of a “Mindful Experience” offering reduced portions for diners on the injections.
- Coverage explains that GLP‑1 medications, developed for type 2 diabetes, suppress appetite and have prompted some restaurants to test smaller‑portion options.
- Ramsay also criticized phone‑wielding influencers for disrupting service, as his group continues to expand with projects including a British‑style gastropub at Disneyland Resort.